Top

BMC Neurology

Published in:

Open Access 01-12-2021 | Myalgie | Research article

Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Authors: Ahmed Yassin, Mohammed Nawaiseh, Ala Shaban, Khalid Alsherbini, Khalid El-Salem, Ola Soudah, Mohammad Abu-Rub

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

The spectrum of neurological involvement in COVID-19 is not thoroughly understood. To the best of our knowledge, no systematic review with meta-analysis and a sub-group comparison between severe and non-severe cases has been published. The aim of this study is to assess the frequency of neurological manifestations and complications, identify the neurodiagnostic findings, and compare these aspects between severe and non-severe COVID-19 cases.

Methods

A systematic search of PubMed, Scopus, EBSCO, Web of Science, and Google Scholar databases was conducted for studies published between the 1st of January 2020 and 22nd of April 2020. In addition, we scanned the bibliography of included studies to identify other potentially eligible studies. The criteria for eligibility included studies published in English language (or translated to English), those involving patients with COVID-19 of all age groups, and reporting neurological findings. Data were extracted from eligible studies. Meta-analyses were conducted using comprehensive meta-analysis software. Random-effects model was used to calculate the pooled percentages and means with their 95% confidence intervals (CIs). Sensitivity analysis was performed to assess the effect of individual studies on the summary estimate. A subgroup analysis was conducted according to severity. The main outcomes of the study were to identify the frequency and nature of neurological manifestations and complications, and the neuro-diagnostic findings in COVID-19 patients.

Results

44 articles were included with a pooled sample size of 13,480 patients. The mean age was 50.3 years and 53% were males. The most common neurological manifestations were: Myalgia (22.2, 95% CI, 17.2 to 28.1%), taste impairment (19.6, 95% CI, 3.8 to 60.1%), smell impairment (18.3, 95% CI, 15.4 to 76.2%), headache (12.1, 95% CI, 9.1 to 15.8%), dizziness (11.3, 95% CI, 8.5 to 15.0%), and encephalopathy (9.4, 95% CI, 2.8 to 26.6%). Nearly 2.5% (95% CI, 1 to 6.1%) of patients had acute cerebrovascular diseases (CVD). Myalgia, elevated CK and LDH, and acute CVD were significantly more common in severe cases. Moreover, 20 case reports were assessed qualitatively, and their data presented separately.

Conclusions

Neurological involvement is common in COVID-19 patients. Early recognition and vigilance of such involvement might impact their overall outcomes.

Available only for authorised users

Johns Hopkins. Corona Virus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins. Available at: https://coronavirus.jhu.edu/map.html.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMed

Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5. https://doi.org/10.1002/jmv.25728.CrossRefPubMed

Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2020;12(1):14.CrossRef

Pleasure SJ, Green AJ, Josephson SA. The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines: neurologists move to the frontlines. JAMA Neurol. 2020;77(6):679–80. https://doi.org/10.1001/jamaneurol.2020.1065.CrossRefPubMed

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–90. https://doi.org/10.1001/jamaneurol.2020.1127.CrossRefPubMed

Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RH. First case of 2019 novel coronavirus disease with encephalitis. ChinaXiv. 2020;202003:00015.

Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus. 2020;12(3):e7352. Published 2020 Mar 21. https://doi.org/10.7759/cureus.7352.

Marchese-Ragona R, Ottaviano G, Piero N, Vianello A, Miryam C. Sudden hyposmia as a prevalent symptom of COVID-19 infection. medRxiv. 2020; Available from: https://doi.org/10.1101/2020.04.06.20045393.

10.

Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, et al. Acute cerebrovascular disease following COVID-19: A single center, retrospective, observational study. SSRN Electron J. 2020; Available from. https://doi.org/10.2139/ssrn.3550025.

11.

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55–8. https://doi.org/10.1016/j.ijid.2020.03.062.CrossRefPubMedPubMedCentral

12.

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020;296(2):E119–20. https://doi.org/10.1148/radiol.2020201187.CrossRefPubMed

13.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. https://doi.org/10.1016/j.jclinepi.2009.06.006.CrossRefPubMed

14.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1) Available from:. https://doi.org/10.1186/s13643-016-0384-4.

15.

Health NI of. National Heart Lung, and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. 2014.

16.

Health NI of. Quality Assessment tool for case series studies. The National Heart, Lung, and Blood Institute; 2017.

17.

Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805. https://doi.org/10.1177/0962280216669183.CrossRefPubMed

18.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https://doi.org/10.1186/1471-2288-14-135.CrossRefPubMedPubMedCentral

19.

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. https://doi.org/10.1186/1471-2288-5-13.CrossRefPubMedPubMedCentral

20.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral

21.

Group OL of EW. The Oxford levels of evidence 2: Oxford centre for evidence-based medicine. University of Oxford; 2011.

22.

Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. https://doi.org/10.1172/JCI137244.

23.

Liu YS, Zhang D, Tang S, Chen H, Chen L, He X, Tong M, Liu M, Lin Y, Zhu B, Su X The Epidemiological and Clinical Characteristics of 2019 Novel Coronavirus Infection in Changsha, China. 2020. Available at SSRN: https://ssrn.com/abstract=3537093 or https://doi.org/10.2139/ssrn.3537093.

24.

Wang L, Gao YH, Lou LL, Zhang GJ. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J. 2020;55(4):2000398. Published 2020 Apr 23. https://doi.org/10.1183/13993003.00398-2020.

25.

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020;71(15):889–90. https://doi.org/10.1093/cid/ciaa330.CrossRefPubMed

26.

Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47(5):1275–80. https://doi.org/10.1007/s00259-020-04735-9.CrossRefPubMed

27.

Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002–9. https://doi.org/10.1136/gutjnl-2020-320926.CrossRefPubMed

28.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. https://doi.org/10.1016/S0140-6736(20)30211-7.CrossRefPubMedPubMedCentral

29.

Li J, Li S, Cai Y, Liu Q, Li X, Zeng Z, et al. Epidemiological and clinical characteristics of 17 hospitalized patients with 2019 novel Coronavirus infections outside Wuhan, China. medRxiv. 2020. Available from. https://doi.org/10.1101/2020.02.11.20022053.

30.

Qian G-Q, Yang N-B, Ding F, Ma AHY, Wang Z-Y, Shen Y-F, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-Centre case series. QJM. 2020;113(7):474–81. https://doi.org/10.1093/qjmed/hcaa089.CrossRefPubMedPubMedCentral

31.

Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. [published correction appears in BMJ. 2020 Feb 27;368:m792]. BMJ. 2020;368:m606. Published 2020 Feb 19.

32.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.CrossRefPubMedPubMedCentral

33.

Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020;92(7):797–806. https://doi.org/10.1002/jmv.25783.CrossRefPubMed

34.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.CrossRefPubMedPubMedCentral

35.

Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025–31. https://doi.org/10.1097/CM9.0000000000000744.CrossRefPubMedPubMedCentral

36.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China. Jama. 2020;323(11):1061–9. https://doi.org/10.1001/jama.2020.1585.CrossRefPubMed

37.

Qin X, Qiu S, Yuan Y, Zong Y, Tuo Z, Li J, et al. Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China. 2020. Available at SSRN: https://ssrn.com/abstract=3541147 or https://doi.org/10.2139/ssrn.3541147.

38.

Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388–93. https://doi.org/10.1016/j.jinf.2020.02.016.CrossRefPubMedPubMedCentral

39.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–8. https://doi.org/10.1093/cid/ciaa248.CrossRefPubMed

40.

Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel Coronavirus in the early stage. bioRxiv. 2020. Available from:. https://doi.org/10.1101/2020.02.10.20021584.

41.

Easom N, Moss P, Barlow G, Samson A, Taynton T, Adams K, et al. Sixty-eight consecutive patients assessed for COVID-19 infection: experience from a UK regional infectious diseases unit. Influenza Other Respir Viruses. 2020;14(4):374–9. https://doi.org/10.1111/irv.12739.CrossRefPubMedPubMedCentral

42.

Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, Wang K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J. 2020;133(11):1261–7. https://doi.org/10.1097/CM9.0000000000000824.CrossRefPubMedPubMedCentral

43.

Huang Y, Tu M, Wang S, Chen S, Zhou W, Chen D, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Med Infect Dis. 2020;36:101606.CrossRefPubMedPubMedCentral

44.

Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa270. Online ahead of print.

45.

Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404–10. https://doi.org/10.26355/eurrev_202003_20711.CrossRefPubMed

46.

Guo T-M, Tong Y, Chen J, Huang L, Cheng B, Zhoue J. Clinical features predicting mortality risk in older patients with COVID-19. SSRN Electron J. 2020; Available from:. https://doi.org/10.2139/ssrn.3569846.

47.

Yan X, Wang C, Peng D, Han X, Fan Y, Fang Z, et al. Clinical features, treatment and outcomes of 218 patients with COVID-19: A retrospective, multicenter study based on clinical classification. SSRN Electron J. 2020; Available from:. https://doi.org/10.2139/ssrn.3559594.

48.

Chang D, Lin M, Wei L, Xie L, Zhu G, Cruz CSD, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. Jama. 2020;323(11):1092–3. https://doi.org/10.1001/jama.2020.1623.CrossRefPubMedPubMedCentral

49.

Wang R, Pan M, Zhang X, Fan X, Han M, Zhao F, et al. Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis. 2020;95:421–8. https://doi.org/10.1016/j.ijid.2020.03.070.CrossRefPubMedPubMedCentral

50.

Zhou J, Sun J-J, Cao Z-Q, Wang W-C, Huang K, Zheng F, et al. Epidemiological and clinical features of 201 COVID-19 patients in Changsha, China. Research Square. 2020. Available from:. https://doi.org/10.21203/rs.3.rs-17313/v1.

51.

Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol. 2020;127:104366. https://doi.org/10.1016/j.jcv.2020.104366.CrossRefPubMedPubMedCentral

52.

Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268–70. https://doi.org/10.1056/NEJMc2008597.CrossRefPubMed

53.

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–61. https://doi.org/10.1007/s00405-020-05965-1.CrossRefPubMedPubMedCentral

54.

Chen W, Chen C, Huang L, Ye K, Lv L, Qin Z, et al., Clinical Characteristics of 85 Patients Infected by SARS-CoV-2 in Guangxi, China (2020). Available at SSRN: https://ssrn.com/abstract=3559599 or /link?doi=10.2139/ssrn.3559599CrossRef

55.

Jiang X, Tao J, Wu H, Wang Y, Zhao W, Zhou M, et al. Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China. medRxiv. 2020. Available from:. https://doi.org/10.1101/2020.04.10.20060335.

56.

Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. https://doi.org/10.1016/j.jcv.2020.104364.CrossRefPubMedPubMedCentral

57.

Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, et al. The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan. medRxiv. 2020. Available from:. https://doi.org/10.1101/2020.03.18.20038125.

58.

Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. Travel Med Infect Dis. 2020;35:101664. https://doi.org/10.1016/j.tmaid.2020.101664.CrossRefPubMedPubMedCentral

59.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. [published correction appears in lancet. 2020 mar 28;395(10229):1038] [published correction appears in lancet. 2020 mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

60.

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA. 2020;323(20):2089–90. https://doi.org/10.1001/jama.2020.6771.CrossRefPubMedPubMedCentral

61.

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50. https://doi.org/10.1016/j.thromres.2020.04.041.CrossRefPubMedPubMedCentral

62.

COVID-19 National Incident Room Surveillance Team. COVID-19, Australia: Epidemiology Report 12 (Reporting week to 23:59 AEST 19 April 2020). Commun Dis Intell (2018). 2020;44. Available from. https://doi.org/10.33321/cdi.2020.44.36.

63.

Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S. Acute myelitis after SARS-CoV-2 infection: a case report. medRxiv. 2020. Available from:. https://doi.org/10.1101/2020.03.16.20035105.

64.

Villalba NL, Maouche Y, Ortiz MBA, Sosa ZC, Chahbazian JB, Syrovatkova A, et al. Anosmia and dysgeusia in the absence of other respiratory diseases: should COVID-19 infection be considered? Eur J Case Rep Intern Med. 2020;7:001641. https://doi.org/10.12890/2020_001641.

65.

Ollarves-Carrero MF, Rodriguez-Morales AG, Bonilla-Aldana DK, Rodriguez-Morales AJ. Anosmia in a healthcare worker with COVID-19 in Madrid, Spain. Travel Med Infect Dis. 2020;35:101666. https://doi.org/10.1016/j.tmaid.2020.101666.CrossRefPubMedPubMedCentral

66.

Sharifi-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect. 2020;35(100669):100669. https://doi.org/10.1016/j.nmni.2020.100669.CrossRefPubMedPubMedCentral

67.

Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord. 2020;42(102120):102120. https://doi.org/10.1016/j.msard.2020.102120.CrossRefPubMedPubMedCentral

68.

Karimi N, Sharifi Razavi A, Rouhani N. Frequent convulsive seizures in an adult patient with COVID-19: A case report. Iran Red Crescent Med J. 2020;22(3) Available from:. https://doi.org/10.5812/ircmj.102828.

69.

Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–4. https://doi.org/10.1016/S1474-4422(20)30109-5.CrossRefPubMedPubMedCentral

70.

Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. 2020;58(3):299–301. https://doi.org/10.4193/Rhin20.114.CrossRefPubMed

71.

Hjelmesæth J, Skaare D. Loss of smell or taste as the only symptom of COVID-19. Tidsskr Nor Laegeforen. 2020;140(7) Available from:. https://doi.org/10.4045/tidsskr.20.0287.

72.

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574–6. https://doi.org/10.1056/NEJMc2009191.CrossRefPubMed

73.

Suwanwongse K, Shabarek N. Rhabdomyolysis as a Presentation of 2019 Novel Coronavirus Disease. Cureus. 2020;12(4):e7561. https://doi.org/10.7759/cureus.7561.

74.

Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752–5. https://doi.org/10.1111/jth.14828.CrossRefPubMed

75.

Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64–8. https://doi.org/10.5582/bst.2020.01030.CrossRefPubMed

76.

Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J. 2020;133(9):1015–24. https://doi.org/10.1097/CM9.0000000000000722.CrossRefPubMedPubMedCentral

77.

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–1. https://doi.org/10.1056/NEJMc2001468.CrossRefPubMedPubMedCentral

78.

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441–7. https://doi.org/10.1002/jmv.25689.CrossRefPubMedPubMedCentral

79.

Chen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. bioRxiv. 2020. Available from:. https://doi.org/10.1101/2020.04.07.030650.

80.

Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. https://doi.org/10.1002/path.1570.CrossRefPubMedPubMedCentral

81.

Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020;88:945–6. https://doi.org/10.1016/j.bbi.2020.04.017.CrossRefPubMedPubMedCentral

82.

Robinson CP, Busl KM. Neurologic Manifestations of Severe Respiratory Viral Contagions. Crit Care Explor. 2020;2(4):e0107. Published 2020 Apr 29. https://doi.org/10.1097/CCE.0000000000000107.

83.

Sohal S, Mossammat M. COVID-19 Presenting with Seizures. IDCases; 2020. p. e00782.

84.

Vohora D, Jain S, Tripathi M, Potschka H. COVID-19 and seizures: is there a link? Epilepsia. 2020 Sep;61(9):1840–53. https://doi.org/10.1111/epi.16656.CrossRefPubMed

85.

Nath A. Neurologic complications of coronavirus infections. Neurology. 2020;94(19):809–10. https://doi.org/10.1212/WNL.0000000000009455.CrossRefPubMed

86.

Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020 Jul;92(7):699–702. https://doi.org/10.1002/jmv.25915.CrossRefPubMed

87.

Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–24. https://doi.org/10.1084/jem.20050828.CrossRefPubMedPubMedCentral

88.

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1–5.CrossRef

89.

Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75. https://doi.org/10.1128/JVI.00737-08.CrossRefPubMedPubMedCentral

90.

Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7. https://doi.org/10.1038/s41591-020-0868-6.CrossRefPubMedPubMedCentral

91.

Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance. Otolaryngol Head Neck Surg. 2020;163(1):12–5. https://doi.org/10.1177/0194599820926464.CrossRefPubMed

92.

Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med Res Rev. 2015;35(3):437–63. https://doi.org/10.1002/med.21343.CrossRefPubMed

93.

Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203(2):622–30. https://doi.org/10.1002/path.1560.CrossRefPubMedPubMedCentral

94.

Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, et al. Musculoskeletal consequences of COVID-19. J Bone Joint Surg Am. 2020;102(14):1197–204. https://doi.org/10.2106/JBJS.20.00847.CrossRefPubMed

95.

Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021;13(3):202–6. https://doi.org/10.1136/neurintsurg-2020-016794.CrossRefPubMed

96.

Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020;18(9):2191–201. https://doi.org/10.1111/jth.14994.CrossRefPubMed

97.

Mankad K, Perry MD, Mirsky DM, Rossi A. COVID-19: a primer for Neuroradiologists. Neuroradiology. 2020;62(6):647–8. https://doi.org/10.1007/s00234-020-02437-5.CrossRefPubMedPubMedCentral

98.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.CrossRefPubMedPubMedCentral

99.

Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res. 2020;126(10):1443–55. https://doi.org/10.1161/CIRCRESAHA.120.317055.CrossRefPubMed

100.

Temporary emergency guidance to US stroke centers during the coronavirus disease 2019 (COVID-19) pandemic: on behalf of the American Heart Association/American Stroke Association stroke council leadership. Stroke. 2020;51(6):1910–2. https://doi.org/10.1161/STROKEAHA.120.030023.

101.

Siegler JE, Heslin ME, Thau L, Smith A, Jovin TG. Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center. J Stroke Cerebrovasc Dis. 2020;29(8):104953. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104953.CrossRefPubMedPubMedCentral

102.

Sharma M, Lioutas V-A, Madsen T, Clark J, O’Sullivan J, Elkind MSV, et al. Decline in stroke alerts and hospitalisations during the COVID-19 pandemic. Stroke Vasc Neurol. 2020;5(4):403–5. https://doi.org/10.1136/svn-2020-000441.CrossRefPubMedPubMedCentral

103.

Zhao J, Li H, Kung D, Fisher M, Shen Y, Liu R. Impact of the COVID-19 epidemic on stroke care and potential solutions. Stroke. 2020;51(7):1996–2001. https://doi.org/10.1161/STROKEAHA.120.030225.CrossRefPubMed

104.

Aguiar de Sousa D, Sandset EC, Elkind MSV. The curious case of the missing strokes during the COVID-19 pandemic. Stroke. 2020;51(7):1921–3. https://doi.org/10.1161/STROKEAHA.120.030792.CrossRefPubMed

105.

Cerase A, Guazzi G, Mazzei MA. Letter by Cerase et al regarding article, “temporary emergency guidance to US stroke centers during the COVID-19 pandemic”. Stroke. 2020;51(7):e139–40. https://doi.org/10.1161/STROKEAHA.120.030147.CrossRefPubMed

106.

Siddiqui J, Bala F, Sciacca S, Falzon AM, Benger M, Matloob SA, et al. COVID-19 stroke apical lung examination study: a diagnostic and prognostic imaging biomarker in suspected acute stroke. AJNR Am J Neuroradiol. 2021;42(1):138–43. https://doi.org/10.3174/ajnr.A6832.CrossRefPubMedPubMedCentral

107.

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4. https://doi.org/10.1126/science.abb8925.CrossRefPubMed

108.

Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000. https://doi.org/10.1055/s-0040-1710018.CrossRefPubMedPubMedCentral

109.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8. https://doi.org/10.1007/s00134-020-05991-x.CrossRefPubMed

110.

Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413(116832):116832. https://doi.org/10.1016/j.jns.2020.116832.CrossRefPubMedPubMedCentral

111.

Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194(105921):105921. https://doi.org/10.1016/j.clineuro.2020.105921.CrossRefPubMedPubMedCentral

112.

Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104–20. https://doi.org/10.1093/brain/awaa240.CrossRefPubMedPubMedCentral

113.

Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020;77:8–12. https://doi.org/10.1016/j.jocn.2020.05.017.CrossRefPubMedPubMedCentral

114.

Kim J-E, Heo J-H, Kim H, Song S, Park S-S, Park T-H, et al. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol. 2017;13(3):227–33. https://doi.org/10.3988/jcn.2017.13.3.227.CrossRefPubMedPubMedCentral

115.

Sharma K, Tengsupakul S, Sanchez O, Phaltas R, Maertens P. Guillain–Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report. SAGE Open Med Case Rep. 2019;7:2050313X19838750.PubMedPubMedCentral

Title: Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis
Authors: Ahmed Yassin
Mohammed Nawaiseh
Ala Shaban
Khalid Alsherbini
Khalid El-Salem
Ola Soudah
Mohammad Abu-Rub
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Myalgie
Myalgia
COVID-19
Coronavirus
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02161-4

2024 ASCO Annual Meeting

Springer Medicine

Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Prognostic nutritional index predicts clinical outcomes in patients with cerebral venous sinus thrombosis

Hemichorea in a patient with ipsilateral cortical infarction: a case report

Dorsolateral medullary infarction registry: a study protocol for a prospective, multicentric registry

Quantitative assessments of pupillary light reflexes in hospital-onset unresponsiveness

A different point of view: the evaluation of motor imagery perspectives in patients with sensorimotor impairments in a longitudinal study

Enriched Music-supported Therapy for chronic stroke patients: a study protocol of a randomised controlled trial